Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-09-19
2011-10-18
Ha, Julie (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S029000, C530S300000, C530S314000, C530S328000, C530S329000
Reexamination Certificate
active
08039227
ABSTRACT:
Methods for diagnosing a kidney disease, or the risk thereof, in a subject are provided. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease.
REFERENCES:
patent: 2004/0101874 (2004-05-01), Ghosh et al.
patent: 2007/0050146 (2007-03-01), Bentwich et al.
patent: 2007/0105133 (2007-05-01), Clarke et al.
patent: 2007/0111245 (2007-05-01), Thadhani et al.
Yates NA, Deyanova EG, Geissler W, Wiener MC, Sachs JR, Wong KK, Thornberry NA, Toy RS, Settlage RE, Hendrickson RC, “Identification of peptidase substrates in human plamsma by FTMS based differential mass spectrometry,” International Journal of Mass Spectrometry, 2007, 259: 174-183. Available online Oct. 23, 2006.
CDC, Burrows et al., “Incidence of end-stage renal disease among persons with diabetes—United States, 1990-2002,” MMWR Morb Mortal Wkly Rep. 54, 2005, pp. 1097-1100.
Morrison et al., “Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma,” Biochem J., 385, 2005, pp. 595-603.
Morrison et al., “Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappaB activation,” J Biol Chem., 282, 2007, pp. 15349-15356.
Spiro et al., “Studies on the biosynthesis of the hydroxylysine-linked disaccharide unit of basement membranes and collagens. III. Tissue and subcellular distribution of glycosyltransferases and the effect of various conditions on the enzyme levels,” J Biol Chem., 246, 1971, pp. 4919-4925.
Striker et al., “Diabetic nephropathy: molecular analysis of extracellular matrix and clinical studies update,” Nephrol Dial Transplant., 11 Suppl, 5, 1996, pp. 58-61.
Kanetsuna et al., “Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes,” Am J Physiol Renal Physiol., 291, 2006, pp. F1315-1322.
Akahori et al., “Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression,” J Pharmacol Exp Ther., 314, 2005, pp. 514-521.
Benigni et al., “Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat,” J Am Soc Nephrol., 14, 2003, pp. 1816-1824.
Guha et al., “Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes,” Faseb J., 21, 2007, pp. 3355-3368.
Nerlich et al., “Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions,” Am J Pathol., 139, 1991, pp. 889-899.
Watanabe et al., “Serum or urinary concentration of type IV collagen in diabetics,” J Diabet Complications., 5, 1991, pp. 191-192.
Yagame et al., “Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay,” J Clin Lab Anal., 11, 1997, pp. 110-116.
Iijima et al., “Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy,” J Clin Lab Anal., 12, 1998, pp. 378-382.
Cohen et al., “Increased collagen IV excretion in diabetes. A marker of compromised filtration function,” Diabetes Care, 24, 2001, pp. 914-918.
Ellis et al., “Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy,” Clin. Chem., 44, 1998, pp. 950-956.
Weissinger et al., “Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes,” Kidney Int., 65, 2004, pp. 2426-2434.
Mischak et al., “Proteomic analysis for the assessment of diabetic renal damage in humans,” Clin Sci (Lond)., 107, 2004, pp. 485-495.
Rossing et al., “Impact of diabetic nephropathy and angiotensin II receptor blockage on urinary polypeptide patterns,” Kidney Int., 68, 2005, pp. 193-205.
Decramer et al., “Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis,” Nat Med., 12, 2006, pp. 398-400.
Wittke et al., “Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers,” J Chromatogr A., 1013, 2003, pp. 173-181.
Fiedler et al., “Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,” Clin Chem., 53, 2007, pp. 421-428.
Giorgino et al., “Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study,” Diabetologia., 47, 2004, pp. 1020-1028.
Perkins et al., “Regression of microalbuminuria in type 1 diabetes,” N. Engl. J. Med., 348, 2003, pp. 2285-2293.
Araki et al., “Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes,” Diabetes, 54, 2005, pp. 2983-2987.
Perkins et al., “Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes,” J Am Soc Nephrol., 18, 2007, pp. 1353-1361.
Perkins et al., “Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study,” J.Am.Soc.Nephrol., 16, 2005, pp. 1404-1412.
Brehm et al., “Intracellular localization of human inositol 1, 3, 4, 5, 6-pentakisphosphate 2-kinase,” Biochem J., 408 (3), 2007, pp. 335-345.
Anderson et al., “RNA granules,” J Cell Biol., 172, 2006, pp. 803-808.
Verbsky et al., “The synthesis of inositol hexakisphosphate. Characterization of human inositol 1, 3, 4, 5, 6-pentakisphosphate 2-kinase,” J Biol Chem., 277, 2002, pp. 31857-31862.
Verbsky et al., “The pathway for the production of inositol hexakisphosphate in human cells,” J Biol Chem., 280, 2005, pp. 1911-1920.
Alcazar-Roman et al., “Inositol hexakisphosphate and Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export,” Nat Cell Biol., 8, 2006, pp. 711-716.
Wang et al., “Apical junctional complexes and cell polarity,” Kidney Int., 72, 2007, pp. 1448-1458.
Kiener et al., “Tjp3/zo-3 is critical for epidermal barrier function in zebrafish embryos,” Dev Biol., 316, 2008, pp. 36-49.
Sharma et al., “Adiponectin regulates albuminuria and podocyte function in mice,” J Clin Invest., 118(5), 2008, pp. 1645-1656.
Tan et al., “Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy,” Am J Physiol Renal Physiol., 293(4), 2007, pp. F1026-F1035.
Pavkov et al., “Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indiana,” Kidney Int., 70, 2006, pp. 1840-1846.
Hovind et al., “Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes,” Diabetes Care, 26, 2003, pp. 1258-1264.
Hovind et al., “Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study,” BMJ., 328, 2004, p. 1105.
ISA/US, International Search Report and Written Opinion of International Application No. PCT/US08/77091, mailed Feb. 13, 2009.
Merchant et al, “Proteomics and diabetic nephropathy,” Current Diabe
Boratyn Grzegorz
Klein Jon B.
Merchant Michael
Ha Julie
Stites & Harbison PLLC
University of Louisville Research Foundation Inc.
Wright Terry L.
LandOfFree
Peptide biomarkers predictive of renal function decline and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide biomarkers predictive of renal function decline and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide biomarkers predictive of renal function decline and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298619